Amicus Therapeutics Leads The Holistic Health Industry

Amicus Rx Therapeutics has over 10+ years of expertise in pharmaceuticals and are currently based in Cranbury, New Jersey. They specialize in exclusive rare and orphaned diseases associated with lysosomal disorders. Amicus Therapeutics is focused on research studies that will benefit patients prone to these diseases. Thousands of people face debilitating diseases with minimal care which is focused on limited case studies. Combined with other like minded partners they have raised millions of dollars in funding and have great stock options on the NASDAQ. Their stockholders are proud of their growth in pharmaceuticals and have agreed to back their further growth initiative 100%.

Chief executive officers, John Crowley (Amicus Therapeutics: Small Biotech Seems To Have The ‘Big Mo’), has a lot vested in pharmaceuticals and is there for the long haul. He aspires to improve the quality of health and happiness for thousands of people around the world. In fact, he believes quality healthcare should be affordable and readily accessible to all the people who need it along with their prescription medication. Their primary focus at Amicus Therapeutics is enzyme replacement therapy while sparking the interest of several big name capital venture firms. If you’re suffering from a debilitating illness, they were established with your needs in mind. They make it easier to get treatment for all people regardless of your economic stability.

Their patients enjoy getting treatment that gives them a shorter recovery time versus traditional treatment. They offer their customers advanced technology and actual clinical trials performed on patients with similar illnesses in defense of your remission and recovery. Amicus thrives on helping you get healthy and not their patients quota versus other competitor big name pharmaceutical companies. Get genuine care that is centered around putting the patients needs first. They’re responsible for the recovery and improved health of thousands of patients worldwide.

You’re invited to learn more about Amicus Therapeutics by visiting their website for more details and donation projects for additional clinical trials. They are actively working to improve the life o one patient at a time. Become an active member and save a life with your generous donation. Amicus stands for an improved quality of life for everyone.

Looking to start a new career with Amicus Therapeutics? Visit this website,-NJ-jobs.html

Innovacare’s Rick Shinto Partners with HHS to Enhance and Reform Healthcare

Rick Shinto has a massive amount of experience holding executive positions in the medical industry. In addition to being the CEO of Innovacare, he is also the CEO of MMM Holdings. Previously, Dr. Shinto was the Chief Medical Officer and Chief Officer of Operations for Medical Pathways Management Company. From 1995 to 1997, he was the President of Medical Management for MedPartners. He held yet another position in the medical industry as the Chief Medical Officer of Cal Optima MedPlan. As an esteemed businessman, he won the award of Ernst & Young Entrepreneur of The Year in the service category

Accomplishing the mission
Rick Shinto serves as the President and CEO of Innovacare, he takes the lead in accomplishing the company’s goals. Shinto has more than 20 years of experience in healthcare. He’s worked with NAMM California as the Chief Medical Officer. Shinto is an advocate for the mission of reforming the United States healthcare system. This goal will be achieved by a means of providing new, alternative payment methods that allow patients to pay by the quality of service provided. The current system is based on quantity, not quality. The goal is to have 50% of payments paid to providers through alternative payment methods (APM) by the end of 2018.

HHS and Innovacare launch Medicare payment model initiative
Health & Human Services (HHS) has a goal to revolutionize the medical payment industry. Under the new model, patients will be able to pay for their healthcare according to quality of service. HHS is working by creating compelling incentives for hospitals to reduce the cost of care while increasing the quality of care.

It is expected that this payment model will result in faster recovery of patients and less readmissions. HHS proposed three new healthcare models which will bundle payment models for cardiac care, hip surgery, other surgeries, and increase cardiac rehab utilization. This will give payment incentives to physicians using bundled payment models through the Quality Payment Program.

New additions to Innovacare’s leadership team
Penelope Kokkinides is one of three new executives appointed to the Innovacare Health leadership team. She has entered the company as the Chief Administrative Officer with more than 20 years of experience working with Medicare and Medicaid. Her speciality lies in these government programs as well as overseeing healthcare processes. She has a background as the EVP and COO of Centerlight Healthcare and COO of Touchstone Health.

Mike Sortino is the new Chief Accounting Officer of Innovacare and has experience as the CFO of HCC Specialty. Prior, he worked for Houston Casualty Company as a managing general agent. He has more than two decades of experience with reinsurance and insurance. He’s also served as Controller of Samsung Fire & Marine Insurance Co just prior to joining Innovacare.

Jonathan Meyers was also brought into Innovacare as the Chief Actuary Officer. Beforehand, he was the Director of Actuarial Services for Horizon BCBS and the Chief Actuary at Healthcare Partners New York. He’s well versed in the area of employee benefits, having done this for large organizations including International Paper, SEIU 1199, Johnson & Johnson, and more. Shinto has no doubt selected these executives based upon the fact that they will deliver based upon their extensive experience.


Source: Innovacare Health Announces Additions to Leadership